Home
Resources
Diseases
Compendium
Training
Evaluation
The Tool
The Tutorial
The Dashboard
SYSVAC
About
Registry
E-learning courses
News
Webinars
Network
Steering Committee
Vision and Mission
Map
Meetings
Partners
Join us
Home
Resources
Resources
Type of publications
Guidelines (35)
NITAG documentation (1607)
Reports (58)
SAGE documentation (225)
Scientific publications (114)
Systematic reviews (SYSVAC) (2906)
Regions
Africa (284)
Americas (770)
Eastern Mediterranean (50)
Europe (716)
South-East Asia (82)
Western Pacific (208)
Diseases
Chikungunya (9)
Cholera (35)
COVID-19 (1533)
Cytomegalovirus (1)
Dengue (40)
Diphtheria (80)
Ebola (16)
Escherichia coli (ETEC) (2)
Haemophilus influenzae type B (68)
Hepatitis A (64)
Hepatitis B (159)
Hepatitis C (4)
Hepatitis E (5)
Herpes simplex (1)
Herpes zoster (73)
HIV / AIDS (10)
Human papillomavirus (HPV) (501)
Influenza (595)
Japanese encephalitis (34)
Lyme disease, Borreliosis (1)
Malaria (29)
Measles (134)
Meningococcal disease (148)
Moraxella catarrhalis (1)
Mpox (55)
Mumps (46)
Pertussis (108)
Pneumococcal disease (284)
Poliomyelitis (86)
Q fever (1)
Rabies (30)
Rotavirus (118)
RSV (Respiratory syncytial virus) (56)
Rubella (65)
Salmonella (3)
Shigella (1)
Smallpox (16)
Streptococcus group B (6)
Tetanus (60)
Tick-borne encephalitis (12)
Tuberculosis (78)
Typhoid (25)
Varicella (74)
Yellow fever (42)
Zika (1)
Show more
4945 results found
2024
∙
SAGE
WHO position paper on dengue vaccines – May 2024
2024
∙
NIAC
NIAC Herpes Zoster vaccine recommendations
2024
∙
NACI
Economic Evidence Supplementary Appendix to the Recommendations for Public Health Programs on the Use of Pneumococcal Vaccines in Children, Including the Use of 15-Valent and 20-Valent Conjugate Vaccines
2024
∙
NACI
Recommendations for public health programs on the use of pneumococcal vaccines in children, including the use of 15-valent and 20-valent conjugate vaccines
2024
∙
JCVI
JCVI statement on COVID-19 vaccination in spring 2024 and considerations on future COVID-19 vaccination
2024
∙
NIAC
Updated recommendations for the vaccination of adults against measles
2024
∙
SAGE
Development of WHO immunization policy and strategic guidance
2024
Considerations to inform country COVID-19 vaccination decision-making
2024
∙
ATAGI
ATAGI statement on Nirsevimab for the prevention of severe disease due to respiratory syncytial virus (RSV) in infants
2024
∙
Louise Henaff, Dace Zavadska, Mario Melgar, Johanna Fihman, Christoph Steffen, Joachim Hombach
The role of NITAGs in government decisions on vaccine use: insights from the Fifth Global NITAG Network meeting
Home
Resources
Diseases
Compendium
Training
Evaluation
SYSVAC
News
Webinars
Network
Sign in / Register
